|Videos|October 19, 2021
Patient Case #2 Continued: Novel Second-Generation Antipsychotics
A panel of experts in psychiatry consider the use of a novel second-generation antipsychotic for the management of treatment resistant depression.
Advertisement
Episodes in this series
Advertisement
Related to this article
Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
2
Positive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorder
3
New Analyses of HLP003 for the Adjunctive Treatment of MDD
4
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
5